1. Home
  2. VEON vs CRNX Comparison

VEON vs CRNX Comparison

Compare VEON & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VEON Ltd. ADS

VEON

VEON Ltd. ADS

HOLD

Current Price

$49.78

Market Cap

3.5B

ML Signal

HOLD

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$35.84

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VEON
CRNX
Founded
1992
2008
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.9B
IPO Year
2010
2018

Fundamental Metrics

Financial Performance
Metric
VEON
CRNX
Price
$49.78
$35.84
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
$73.25
$74.78
AVG Volume (30 Days)
130.4K
885.6K
Earning Date
03-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,039,000.00
Revenue This Year
$10.59
$730.30
Revenue Next Year
$7.07
$179.48
P/E Ratio
$6.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$34.55
$24.10
52 Week High
$64.00
$57.99

Technical Indicators

Market Signals
Indicator
VEON
CRNX
Relative Strength Index (RSI) 45.38 27.27
Support Level $44.09 $33.23
Resistance Level $55.96 $37.23
Average True Range (ATR) 3.79 1.63
MACD -0.41 -0.01
Stochastic Oscillator 34.78 6.44

Price Performance

Historical Comparison
VEON
CRNX

About VEON VEON Ltd. ADS

VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

Share on Social Networks: